<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[23andme Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/23andme.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to 23andme]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[23andMe raises prices, splits its health and ancestry analyses]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/23andme-raises-prices-splits-health/20407/]]></link>
		<description><![CDATA[Personal genomics company 23andMe  announced yesterday on its blog  and in an email to customers of impending changes to its product line. Until now 23andMe has offered only two products: its $399 full scan, and a $99 Research Revolution product that  offers limited functionality and a focus...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Sun, 15 Nov 2009 05:59:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/product.html"><![CDATA[product]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/prediction.html"><![CDATA[prediction]]></category>
	</item>
	<item>
		<title><![CDATA[Google puts USD2.6m into biotech startup]]></title>
		<link><![CDATA[http://www.bnet.com/2448-14061_23-314072.html]]></link>
		<description><![CDATA[ Google is investing a further USD2.6m in 23andMe, the privately-held biotech startup launched by the wife of Google co-founder Sergey Brin.          The deal raises Google&#8217;s total investment in the firm to USD7m. Google continues to hold a minority interest in...]]></description>
		<s:doctype><![CDATA[Articles]]></s:doctype>
		<pubDate>Sun, 21 Jun 2009 18:00:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/23andme.html"><![CDATA[23andMe]]></category>
		<category domain="http://resources.bnet.com/topic/sarah+vizard.html"><![CDATA[Sarah Vizard]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
	<item>
		<title><![CDATA[Google-backed personal genetics firm raises USD11m &#8211; Rumour]]></title>
		<link><![CDATA[http://www.bnet.com/2448-14061_23-295325.html]]></link>
		<description><![CDATA[ California-based 23andMe has raised USD11m of a USD24.3m Series B funding round from undisclosed investors, according to peHUB. The firm received Series A funding from investors including Google. The company uses DNA analysis technologies and web-based tools to enable individuals to understand their genetic information. Founded in 2006, 23andMe...]]></description>
		<s:doctype><![CDATA[Articles]]></s:doctype>
		<pubDate>Mon, 04 May 2009 16:52:23 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/analysis.html"><![CDATA[Analysis]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/23andme.html"><![CDATA[23andMe]]></category>
		<category domain="http://resources.bnet.com/topic/editorial.html"><![CDATA[Editorial]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
	<item>
		<title><![CDATA[More on 23andMe and the Future of Personal Genomics]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/1000177/more-on-23andme-and-the-future-of-personal-genomics/]]></link>
		<description><![CDATA[I've been remiss in addressing a particularly thoughtful response to my earlier post on 23andMe's price-cutting and its potential consequences for the future of personal genomics. So let me remedy that.    To recap briefly: 23andMe, the spit-to-read-your-genome company, dropped its subscription price to $399 from $999, a...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 30 Sep 2008 21:09:27 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/google+inc..html"><![CDATA[Google Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/contraction.html"><![CDATA[Contraction]]></category>
		<category domain="http://resources.bnet.com/topic/business.html"><![CDATA[Business]]></category>
		<category domain="http://resources.bnet.com/topic/23andme.html"><![CDATA[23andMe]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/venture+capital.html"><![CDATA[Venture Capital]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/financing+startups.html"><![CDATA[Financing Startups]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
		<category domain="tickers">GOOG</category>
	</item>
	<item>
		<title><![CDATA[23andMe's Price Cut: The End of Commerical Personal Genomics?]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/1000151/23andmes-price-cut-the-end-of-commerical-personal-genomics/]]></link>
		<description><![CDATA[A huge price cut by personal-genomics pioneer 23andMe may well herald the demise of the commercial personal-genomics business before it even really got started -- and for much the same reason that startups such as Celera Genomics saw their genome-based information businesses crash and burn almost a decade ago. by...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 09 Sep 2008 22:01:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/genome.html"><![CDATA[Genome]]></category>
		<category domain="http://resources.bnet.com/topic/database.html"><![CDATA[Database]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/celera+genomics.html"><![CDATA[Celera Genomics]]></category>
		<category domain="http://resources.bnet.com/topic/23andme.html"><![CDATA[23andMe]]></category>
		<category domain="http://resources.bnet.com/topic/snp.html"><![CDATA[SNP]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
</channel>
</rss>
